Increased Anti-Leukemic Activity of Decitabine via AR-42-induced Upregulation of miR-29b: A Novel Epigenetic-Targeting Approach in Acute Myeloid Leukemia

Leukemia - United Kingdom
doi 10.1038/leu.2012.342
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Awareness of Emerging Novel Epigenetic Targeting Therapy in Acute Myeloid Leukemia

Cancer therapy & Oncology International Journal
2018English

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells

Cells
2019English

An Auristatin Nanoconjugate Targeting CXCR4+ Leukemic Cells Blocks Acute Myeloid Leukemia Dissemination

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2020English

Upregulation of Mir-99a Is Associated With Poor Prognosis of Acute Myeloid Leukemia and Promotes Myeloid Leukemia Cell Expansion

Blood
BiochemistryImmunologyCell BiologyHematology
2016English

In Vitro and in Vivo Anti-Leukemic Activity of the Peptidase-Potentiated Alkylator Melflufen in Acute Myeloid Leukemia

Oncotarget
Oncology
2016English

Altered Expression Pattern of miR-29a, miR-29b and the Target Genes in Myeloid Leukemia

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2014English

The Epigenetic Landscape of Acute Myeloid Leukemia

Advances in Hematology
Hematology
2014English

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

PLoS ONE
Multidisciplinary
2010English

Novel Agents in Acute Myeloid Leukemia

International Journal of Hematology
Hematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy